Request Demo

Last update 08 May 2025

Vascular Neoplasms

Last update 08 May 2025

Basic Info

Synonyms

Neoplasm, Vascular, Neoplasms, Vascular, Vascular Neoplasm

+ [12]

Introduction

Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.

Drugs associated with Vascular Neoplasms

Pembrolizumab

Target

PD-1

Mechanism

PD-1 inhibitors

Active Org.

MSD KK

[+82]

Originator Org.

Merck & Co., Inc.

Active Indication

Malignant Pleural Mesothelioma [+553]

Inactive Indication

Adenocarcinoma, metastatic [+74]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date04 Sep 2014

Sirolimus

Target

mTOR

Mechanism

mTOR inhibitors

Active Org.

Santen Pharmaceutical Co., Ltd. [+30]

Originator Org.

Pfizer Inc.

Active Indication

Vascular Malformations [+94]

Inactive Indication

Acute Erythroblastic Leukemia [+123]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date15 Sep 1999

Timolol Maleate

Target

β-adrenoceptors

Mechanism

β-adrenoceptors antagonists

Active Org.

Beijing Merson Pharmaceutical Co. Ltd. [+9]

Originator Org.

Bausch Health Americas, Inc.

Active Indication

Cataract [+5]

Inactive Indication

Vascular Neoplasms

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date17 Aug 1978

Clinical Trials associated with Vascular Neoplasms

NCT04832698

/ RecruitingNot ApplicableIIT

Survey of Current Interventional and Diagnostic Imaging Residents After Participation in Endovascular Simulator Training Regimen

This study looks at the comfort of interventional and diagnostic imaging residents in performing simulated endovascular procedures after completing training on the Mentice endovascular simulator device. Implementation of a training curriculum with radiology residents interested in interventional radiology will help facilitate hands-on training in a low-risk environment and allow for safer future patient encounters.

Start Date08 Jul 2020

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

CTR20181638

/ CompletedPhase 1

评估马来酸噻吗洛尔凝胶在健康中国成年受试者中的安全性、耐受性和药代动力学特征的I期临床研究

[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of timolol maleate gel in healthy Chinese adult subjects

主要目的：评估健康中国成年受试者单次、多次涂抹的马来酸噻吗洛尔凝胶后的安全性、耐受性。次要目的：评估健康中国成年受试者单次、多次涂抹马来酸噻吗洛尔凝胶后噻吗洛尔的药代动力学特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of timolol maleate gel after single and multiple applications in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic characteristics of timolol after single and multiple applications in healthy Chinese adult subjects.

Start Date15 Oct 2018

Sponsor / Collaborator

Shanghai Aucta Pharmaceuticals Co. Ltd.

NCT02721732

/ Active, not recruitingPhase 2IIT

Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.

Start Date15 Aug 2016

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Vascular Neoplasms

100 Translational Medicine associated with Vascular Neoplasms

0 Patents (Medical) associated with Vascular Neoplasms

1,165

Literatures (Medical) associated with Vascular Neoplasms

01 Dec 2025·Journal of Gastrointestinal Cancer

Demographics, Prognostic Factors, and Survival Outcomes in Hepatic Angiosarcoma: A Retrospective Analysis

Article

Author: Yasinzai, Abdul Qahar Khan ; Khan, Marjan ; Robinson, Jaylyn ; Jain, Hritvik ; Sohail, Amir Humza ; Ullah, Asad ; Wali, Agha ; Karki, Nabin R ; Iqbal, Asif ; Khan, Israr ; Fadhil, Nooran

BACKGROUNDHepatic angiosarcoma (HA) is a rare malignant vascular neoplasm. Currently, there are no standardized protocols for treating HA. This study aims to understand clinicopathologic analysis, prognostic factors, and treatment outcomes comprehensively.METHODSThe data retrieved from the SEER database was reviewed for hepatic angiosarcoma cases between 2000 and 2021.RESULTSA total of 389 patients with hepatic angiosarcoma were identified with a mean age of 63.9 years (SD ± 16). Most patients were male (64%), and per US census data, non-Hispanic Asians or Pacific Islanders were the most common race (17%). In known cases of tumor stage (61%), the most common tumor stage was distant (22%), and most were grade III (18%) tumors. Overall, the 3-year survival rate was 6.7% with a 95% confidence interval (95% CI 0.044-0.100), disease-specific survival at a 1-year survival rate was 4.43% (95% CI 0.023-0.083), and no patients survived by 3 years. The best overall survival rate was the 1-year rate for surgical resection, 18.20% (95% CI 0.075-0.441). Chemotherapy had a 1-year survival rate of 11% (95% CI 0.057-0.211), and radiation therapy had no survival significance (p = 0.2). Multivariate analysis shows age above 70 years (H.R. 1.67 (95% CI 1.181-2.381), p < 0.05), no surgical intervention (H.R. 2.29 (95% CI 1.585-3.336) p < 0.001), and distant stage (H.R. 2.54 (95% CI 1.696-3.805) p < 0.001) are negative prognostic factors, whereas female sex (H.R. 0.68 (95% CI 0.536-0.875) p < 0.05) is a positive prognostic factor.CONCLUSIONIncreasing age (> 70 years), male sex, and distant stage were found to be strong predictors of poor survival outcomes. Patients had better outcomes when surgical resection and chemotherapy were included in their treatment. These results can provide continued evidence in the future management of patients with hepatic angiosarcoma.

01 Apr 2025·Annals of Diagnostic Pathology

Primary intrarenal hemangioma – A series of 39 cases

Article

Author: Bayrak, Busra Yaprak ; Faraz, Maria ; Kelemen, Dora ; Akgul, Mahmut ; Subasi, Nusret B ; Lobo, Anandi ; Kuthi, Levente ; Sangoi, Ankur R ; Kaushal, Seema ; Movassaghi, Mehrnaz ; Panizo, Angel ; Mohanty, Sambit K ; Kandukuri, Shivani ; Alghamdi, Mohammed A ; Yörükoğlu, Kutsal ; Bhardwaj, Swati ; Nova-Camacho, Luiz M ; Rosenzweig, Andrew ; Lightle, Andrea A ; Hajiyeva, Sabina ; Martos, María Garcia ; Jha, Shilpy ; Williamson, Sean R

Intrarenal hemangiomas lack concise clinicopathologic information, due to the predominance of single case reports and inclusion of other vascular neoplasms and hemangiomas of perirenal, hilar, and renal vein origin. Herein, in this multi-institutional study we evaluate clinicopathologic features of 39 intrarenal hemangiomas. The median age was 62 years (range = 27-94 years; 2:1 male to female ratio), with left-sided predominance (left = 21, right = 13; one case was bilateral). The median tumor size was 1.5 cm (0.2-10 cm). Two cases arose from transplanted kidneys. Most were asymptomatic (n = 30, 86 %), even though most surgical interventions (19 partial, 19 radical, 1 biopsy) were due to hemangiomas (n = 24, 62 %). Synchronous renal neoplasms were present in 9 (23 %) patients, including clear cell renal cell carcinoma (RCC) (n = 4), angiomyolipoma (n = 2), oncocytoma (n = 2), and chromophobe RCC (n = 1). Multifocal hemangiomas (n = 5) were seen in cases with end stage renal disease. Intrarenal hemangiomas were mostly anastomosing (n = 18; 46 %), followed by capillary (n = 15; 38 %), and cavernous (n = 6; 16 %) subtypes. Fibrin thrombus (n = 9; 23 %) and extramedullary hematopoiesis (n = 4; 10 %) were occasionally present, the latter being only in the anastomosing subtype. Immunohistochemistry was performed on a majority (n = 33, 84 %) of hemangiomas, with vascular markers CD31 and CD34 and lack of PAX8 were most used for diagnosis. 30 patients had follow-up (median 48 months, range 1-241 months), none showed disease progression/recurrence. This study provides comprehensive observation of the largest intrarenal hemangioma cohort, highlighting their frequent cause of surgical intervention when present, predominance of anastomosing subtype, multifocality in end stage kidney disease, and occasional concurrent ipsilateral neoplasms.

01 Apr 2025·European Journal of Obstetrics & Gynecology and Reproductive Biology

A rare case of giant placental chorioangioma causing polyhydramnios and fetal hydrops: A case report and literature review

Review

Author: Wang, Jia-Yue ; Chen, Jian-Jiao

BACKGROUNDPlacental chorioangioma is a benign tumour of the placenta. In most cases, chorioangiomas are small and do not result in maternal or fetal complications. This report presents a case with a large placental chorioangioma, which was associated with an intrapartum event leading to significant maternal and perinatal morbidity.CASE PRESENTATIONA case of placental chorioangioma was diagnosed at 29 + 1 weeks of gestation. As the tumour enlarged progressively with polyhydramnios, further ultrasound examination indicated signs of fetal hydrops. Following multi-disciplinary team discussion, caesarean section was performed with delivery of a female infant. Pathological examination of the placenta confirmed an infarcted chorioangioma.CONCLUSIONSPlacental chorioangiomas are benign, non-trophoblastic vascular neoplasms. While often asymptomatic, they can occasionally have unfavourable outcomes. Ultrasound examination plays a critical role in their diagnosis and monitoring. These neoplasms exhibit a wide range of clinical manifestations, leading to their classification as a spectrum of symptoms rather than a distinct syndrome. Early diagnosis, vigilant prenatal surveillance, and timely intervention are essential to minimize fetal morbidity and mortality.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Vascular Neoplasms

Basic Info

Related

Analysis